Brief: Synact Pharma Reports Positive Phase 1 Results For Drug Candidate AP1189

SynAct Pharma AB

11/02/2019 07:09

Feb 11 (Reuters) - SynAct Pharma AB  SYNACT.TE :
    * REPORTS POSITIVE PHASE 1 RESULTS FOR DRUG CANDIDATE AP1189
    * INTENDS TO BEGIN WORK ON IDENTIFYING OPTIMAL FINANCING
SOLUTION
TO COVER ADDITIONAL COSTS OF PHASE II PROGRAM, ESTIMATED AT
ABOUT SEK 20 MILLION
    * STUDY SHOWS AP1189 IS SECURE AND WELL TOLEARTED UP TO 100
MG ONE
TIME PER DAY DURING 14 DAYS
    * RESULTS FROM PHASE 2 STUDY PLANNED TO BE COMMUNICATED
DURING H2
2020

Source text for Eikon:  ID:nWkr9NQXKY 
Further company coverage:  SYNACT.TE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 587720920;))